MarketFriction

Alivus Life Sciences Ltd

NSE ALIVUS · BSE 543322 · Pharmaceuticals
₹1,374.20 -0.37%
NSE close2026-10-01
52 week range819.00 - 1,493.80
Market cap₹16,658 Cr.
P/E26.8
IPO 2021 · +91% since Price band 20% Delivery 53.2%

Price

Drag to pan, scroll or pinch to zoom. Ruler (or Shift + drag) measures a move.Dashed lines: 52 week high and low. Prices adjusted for splits and bonuses.

Financials

Standalone, Rs crore
Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales595573537589507642650602588673689640
Expenses428400395429373452451430409442475429
Operating Profit167173141159134190198172179231215212
OPM %28%30%26%27%27%30%31%29%30%34%31%33%
Other Income523591010915-122322
Interest000000111111
Depreciation131315141515161718202021
Profit before tax159161130150127185191163174198216212
Tax %25%26%24%26%25%26%26%25%25%24%25%25%
Net Profit1191199811195137142122130150163160
EPS in Rs9.699.697.999.107.7811.1811.589.9110.6012.2513.2513.04
Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales08861,5371,8852,1232,1612,2832,3872,5522,590
Expenses06381,0641,2941,5061,5181,6081,7021,7541,754
Operating Profit-0248473592617643675684798837
OPM %-4.0%28%31%31%29%30%30%29%31%32%
Other Income0-0110142811333448
Interest0134882812255
Depreciation0192933384253617579
Profit before tax-0228421471565629631654751801
Tax %4,200%14%26%25%26%26%25%26%25%
Net Profit-0196313352419467471486564603
EPS in Rs-430.00997.861,597.37358.7434.1738.1138.4339.6345.9949.14
Dividend Payout %0%0%0%0%61%110%59%13%11%
10 Years5 Years3 YearsTTM1 YearLast Year
Compounded Sales Growth%6%6%8%
Compounded Profit Growth%9%6%25%
Stock Price CAGR%15%30%46%
Return on Equity%21%19%18%
Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital0.012222525252525
Reserves-1864007512,0302,1142,3082,7933,308
Borrowings0000319175757
Other Liabilities11,3871,3241,244414545501537594
Total Liabilities01,4751,7261,9972,4712,7022,8503,4113,983
Fixed Assets04565465735957818059551,038
CWIP08011149262106102284
Investments0000000478780
Other Assets09391,1691,4101,7841,8601,9391,8771,881
Total Assets01,4751,7261,9972,4712,7022,8503,4113,983
Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity-010195388598306414392565
Cash from Investing Activity0-9-51-69-122-147-116-616-570
Cash from Financing Activity01-137-214-79-388-279-6-64
Net Cash Flow028106397-22818-230-69
Free Cash Flow-01144322466143285226259
CFO/OP4,800%14%61%84%119%71%85%81%93%
Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days44185152120116136122148153
Inventory Days162441227214185224251237246
Days Payable4120111192110158139137132
Cash Conversion Cycle165424268241190202235248267
Working Capital Days-2,059-186-3712149176188201194
ROCE %529%186%97%42%30%28%25%24%
Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Promoters82.85%82.85%82.85%82.85%75.00%75.00%74.99%74.94%74.91%74.91%74.87%74.87%
FIIs4.39%4.57%5.01%4.81%7.85%6.74%6.57%6.42%6.84%5.08%5.30%5.54%
DIIs0.64%0.74%1.41%1.57%4.16%4.86%5.19%5.62%5.47%7.13%7.27%7.18%
Public12.13%11.84%10.73%10.76%12.99%13.40%13.25%13.03%12.79%12.89%12.55%12.42%
No. of Shareholders1,98,7641,85,5311,56,1831,49,3961,43,9601,46,8401,41,9771,38,5001,35,6431,32,7481,27,9691,25,559

Fundamentals

Market Cap₹ 16,658 Cr.
Current Price₹ 1,357
Stock P/E26.8
Book Value₹ 271
ROCE23.8 %
ROE17.9 %
Dividend Yield0.37 %
Face Value₹ 2.00
Compounded Sales Growth (TTM)8%
Compounded Profit Growth (TTM)25%
Standalone figures.
Valuation
Market capRs 16,839 Cr
Enterprise valueRs 16,824 Cr
P/E (TTM)27.92x
Price to book5.98x
Price to sales6.50x
EV / EBITDA19.01x
EV / EBIT20.87x
EV / sales6.49x
Price to cash flow43.01x
Earnings yield3.58%
Dividend yield0.36%
P/E, 3-year average19.27x
P/B, 3-year average3.68x
P/E, 5-year average17.81x
P/B, 5-year average3.44x
Profitability
Operating margin (excl. other income)28.67%
Operating margin (incl. other income)30.05%
EBITDA margin34.16%
Pre-tax margin30.90%
Net profit margin23.28%
Net margin, latest quarter25.00%
ROE18.86%
ROCE25.14%
ROA15.51%
ROE, 3-year average20.73%
ROCE, 3-year average27.69%
ROA, 3-year average16.84%
ROE, 5-year average30.59%
ROCE, 5-year average44.41%
ROA, 5-year average17.63%
ROIC (approx.)21.35%
Tax rate25.76%
Other income / net worth1.16%
Growth
Sales growth (latest year)4.54%
Profit growth (latest year)3.13%
Sales CAGR, 3 years3.98%
Sales CAGR, 5 years9.20%
Profit CAGR, 3 years5.07%
Profit CAGR, 5 years9.18%
Sales growth QoQ-7.07%
Profit growth QoQ-1.59%
Sales growth YoY (latest quarter)6.41%
Profit growth YoY (latest quarter)31.71%
Per share
EPS (TTM)Rs 49.21
EPS (latest year)Rs 39.63
EPS (latest quarter)Rs 13.06
EPS, 3-year averageRs 38.72
EPS, 5-year averageRs 101.82
Book value per shareRs 229.92
Sales per shareRs 211.40
Cash flow per shareRs 31.95
Free cash flow per shareRs 21.14
Dividend per share (latest year)Rs 5.00
Dividend per share, 3-year averageRs 23.17
Dividend per share, 5-year averageRs 22.63
Dividends
Dividend payout12.62%
Dividend payout, 3-year average60.47%
Dividend payout, 5-year average60.72%
Efficiency
Asset turnover0.70x
Fixed asset turnover2.50x
Inventory turnover1.98x
Inventory days185 days
Debtor days148 days
Debtors turnover2.46x
Creditor days132 days
Cash conversion cycle267 days
Working capital days194 days
Leverage
Total debtRs 57 Cr
Cash and bankRs 71 Cr
Net debtRs -15 Cr
Debt to equity0.02x
Net debt / EBITDA-0.02x
Interest coverage148.43x
Current ratio (filing 2026-03-31)5.21x
Quick ratio (filing 2026-03-31)3.85x
Trade payables (filing 2026-03-31)Rs 372 Cr
Owners' fund to total sources82.59%
Debt to assets1.66%
Cash flow
Cash from Operating Activity (latest year)Rs 392 Cr
Cash from Investing Activity (latest year)Rs -616 Cr
Cash from Financing Activity (latest year)Rs -6 Cr
Net Cash Flow (latest year)Rs -230 Cr
Free cash flow (latest year)Rs 259 Cr
FCFE (approx.: FCF + change in debt)Rs 298 Cr
Cash from ops / profit, 5 years0.95x
Sales to cash flow6.10x
Statement figures
Net sales (TTM)Rs 2,590 Cr
Net sales (latest year)Rs 2,387 Cr
Sales (latest quarter)Rs 640 Cr
Operating profit excl. other income (latest year)Rs 684 Cr
Operating profit (latest quarter)Rs 212 Cr
Other income (TTM)Rs 48 Cr
EBITDA (TTM)Rs 885 Cr
PBDT (TTM)Rs 879 Cr
Profit before tax (TTM)Rs 801 Cr
Tax (latest year)Rs 168 Cr
Net profit (TTM)Rs 603 Cr
Net profit (latest year)Rs 486 Cr
Net profit (latest quarter)Rs 160 Cr
Depreciation (TTM)Rs 79 Cr
Depreciation (latest quarter)Rs 21 Cr
Interest (TTM)Rs 5 Cr
Cost of goods sold (latest year)Rs 1,332 Cr
Total expenditure (latest year)Rs 1,702 Cr
Total income (latest year)Rs 2,420 Cr
Share capitalRs 25 Cr
ReservesRs 2,793 Cr
Shareholders' fundsRs 2,817 Cr
Total assetsRs 3,411 Cr
Net blockRs 955 Cr
Capital work in progressRs 102 Cr
InvestmentsRs 478 Cr
ReceivablesRs 970 Cr
InventoryRs 674 Cr
Other liabilitiesRs 537 Cr
Shares outstanding (crore)12.25
Ownership
Promoter holding74.87% (-0.07 in a year)
Computed by MarketFriction from the standalone statements. Returns use average balances.
P/E 27.9 is at the 89th percentile of its own 5.2-year range (median 22.8, low 13.1, high 31.5).
P/B 5.98 is at the 49th percentile (median 5.98).
Monthly. Market cap from split-adjusted price; profit and book value as reported by that month. A low percentile means cheap versus its own history, not cheap versus peers.
PeriodALIVUSNifty 50Difference
1 week+0.3%-2.8% +3.1 pts
1 month-4.8%-6.8% +2.0 pts
3 months+18.7%-7.6% +26.3 pts
6 months+41.3%+0.4% +40.9 pts
1 year+45.1%-9.9% +55.1 pts
2 years+21.0%-13.6% +34.5 pts
3 years+122.4%+14.2% +108.2 pts
5 years+103.9%+27.9% +76.0 pts
20 mutual fund schemes hold about ₹921 Cr. Over three months 2 bought more and 8 sold (share counts, price move removed).
FundWeightEst. Cr3m shares
Quant Small Cap Fund0.88%313 +20%
Old Bridge Focused Fund3.94%157 -14%
Quant Flexi Cap Fund2.08%153 -1%
Bandhan Large & Mid Cap Fund0.61%128 +36%
ICICI Pru Healthcare Fund-1.21%85 -34%
Quant Healthcare Fund8.08%35 -7%
Helios Small Cap Fund1.02%15 -6%
Motilal Oswal Nifty Microcap 250 Index Fund0.45%11 -5%
Tata Small Cap Fund0.08%11 -91%
Quantum Small Cap Fund2.62%7 -6%
Bandhan Healthcare Fund1.36%5 -0%
Unifi Flexi Cap Fund1.19%3 -4%
Groww Nifty Total Market Index Fund0.02%0 -2%
Bandhan BSE Healthcare Index Fund0.26%0 -2%
Angel One Nifty Total Market Index Fund0.02%0 -1%
Mirae Asset Nifty Total Market Index Fund0.02%0 -2%
Bandhan Nifty Total Market Index Fund0.02%0 -2%
Motilal Oswal BSE 1000 Index Fund0.02%0 -1%
Samco Multi Cap Fund0.00%0 -100%
Navi Aggressive Hybrid Fund0.00%0 -100%

Red flags

F-score 3 of 8
No red flags in the latest statements and filings.
Checks on the latest reported years: cash vs profit, accruals, receivables and inventory vs sales, dilution, debt, interest cover, equity, other income, losses, and auditor, top-management, insolvency and regulator filings in the last 12 months. A flag asks for an explanation; it is not a verdict.

Latest quarter

Jun 2026
Sales ₹640 Cr +6.3% vs Jun 2025. Net profit ₹160 Cr +31.1%.
Against our estimate for Jun 2026: sales +0.9%, profit +13.6% beat. Our estimate for Sep 2026: sales Rs 624 Cr, profit Rs 143 Cr (how).

Activity

Compare
CompanyMcap (Cr)P/EROCE
Sun Pharmaceutical Industries Ltd447,47635.420.5 %
Divis Laboratories Ltd250,36384.022.0 %
Torrent Pharmaceuticals Ltd186,15283.415.2 %
Zydus Lifesciences Ltd119,75024.621.1 %
Cipla Ltd111,43031.115.5 %
Laurus Labs Ltd106,92897.817.8 %
Mankind Pharma Ltd105,12049.313.5 %
Dr Reddys Laboratories Ltd104,49432.413.0 %
Aurobindo Pharma Ltd97,68225.812.9 %
Lupin Ltd93,84015.829.9 %
Glenmark Pharmaceuticals Ltd68,90522.139.8 %
Alkem Laboratories Ltd62,77227.621.2 %
Biocon Ltd61,43984.53.61 %
Abbott India Ltd57,94935.944.8 %
Gland Pharma Ltd49,33343.115.1 %
No bulk or block deals on record.
Ex-dateActionFactor
2026-09-01Dividend - Rs 5 Per Share
2025-09-01Dividend - Rs 5 Per Share
2023-10-17Interim Dividend - Rs 22.50 Per Share
2023-09-22Annual General Meeting
2023-03-24Interim Dividend - Rs 21 Per Share
2022-09-15Dividend - Rs 10.5 Per Share
2021-11-22 Interim Dividend - Rs 10.50 Per Share
DateTypeWhat it says
2026-09-16General UpdatesThe Company has incorporated a wholly owned subsidiary company in Brazil.
2026-09-11Concall / analyst meetSchedule of meet
2026-09-08Shareholder meetingProceedings of Annual General Meeting held on September 08, 2026. Further, the company has submitted the Exchange a copy of Scrutinizers report along ...
2026-09-07Concall / analyst meetSchedule of meet
2026-09-05Concall / analyst meetSchedule of meet
2026-08-25Concall / analyst meetSchedule of Investor/Analyst meeting
2026-08-18Press ReleaseA press release dated August 18, 2026, titled "Alivus Life Sciences announces acquisition of majority stake in IQGenX.".
2026-08-18Board meeting outcomeEnclosed please find herewith intimation pursuant to Regulation 30 of SEBI (LODR), 2015 with respect to acquisition.
2026-08-13Concall / analyst meetSchedule of meet of Investor/Analyst.
2026-08-11UpdatesBusiness Responsibility & Sustainability Report for FY 2025-26.
2026-08-11Shareholder meetingNotice of Annual General Meeting (AGM) to be held on September 8, 2026. Enclosed please find herewith Notice of the 15th AGM.
2026-08-07Concall / analyst meetSchedule of meet
2026-08-07Concall / analyst meetSchedule of meet
2026-08-07Concall / analyst meetTranscript of earnings call held on July 31, 2026.
2026-08-06Record DateRecord date for the purpose of Dividend is 01-Sep-2026.
2026-08-06Shareholder meetingNotice of Annual General Meeting to be held on September 08, 2026
2026-07-31Concall / analyst meetLink of Recording
2026-07-30UpdatesAllotment of Equity Shares under "Employee Stock Option Scheme, 2021".
2026-07-30Investor PresentationInvestor Presentation
2026-07-30Press ReleaseA press release dated July 30, 2026, titled "Press Release of the Company for the First Quarter ended June 30, 2026.".
2026-07-30Board meeting outcomeAlivus Life Sciences Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.
2026-07-23Concall / analyst meetSchedule of meet - Earnings Call
2026-06-23Concall / analyst meetSchedule of meet
2026-06-12Disclosure under SEBI TakeovNirma Limited has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acq...
2026-06-10Concall / analyst meetSchedule of Analyst/ Institutional Investor meeting.
Company filings to NSE, newest first. Routine notices (trading window, newspaper copies) are left out. Click a row for the filing.
No short selling reported to NSE in our files.
Short sales disclosed by brokers to NSE, by trade date. Collected since late September 2026.
Not on any NSE surveillance list in the latest file.

Quick answers

What is the market cap of Alivus Life Sciences Ltd?

Alivus Life Sciences Ltd (ALIVUS) has a market capitalisation of Rs 16,658 Cr. at the 2026-10-01 close.

What is the P/E ratio of Alivus Life Sciences Ltd?

Alivus Life Sciences Ltd trades at a P/E of 26.8 on trailing twelve-month profit, at the 2026-10-01 close.

What were Alivus Life Sciences Ltd's latest quarterly results?

In the Jun 2026 quarter, Alivus Life Sciences Ltd sales was Rs 640 Cr (+6.3% vs Jun 2025) and net profit was Rs 160 Cr.

What is the 52-week high and low of Alivus Life Sciences Ltd?

The 52-week high is Rs 1,493.80 and the 52-week low is Rs 819.00.

Data: NSE and BSE daily reports, company filings. Numbers only, not investment advice, not a SEBI-registered research service.AboutMethodologyFAQResearchContactTermsPrivacyDisclaimerUpdated 2026-10-03